Brief: Camurus Announces FDA Acceptance Of NDA Resubmission For Oclaiz
09/01/2026 15:34
Jan 9 (Reuters) - Camurus AB CAMX.ST: CAMURUS ANNOUNCES FDA ACCEPTANCE OF NDA RESUBMISSION FOR OCLAIZ™ FOR THE TREATMENT OF ACROMEGALY CAMURUS AB - PDUFA TARGET ACTION DATE SET FOR 10 JUNE 2026 CAMURUS AB: PRODUCT RECEIVED MARKETING AUTHORIZATION IN THE EU AND UK IN 2025 UNDER THE PRODUCT NAME OCZYESA, PRODUCT LAUNCH INITIATED IN THE EU Source text: ID:nPnb3TGq7a Further company coverage: CAMX.ST ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Camurus AB
See all newsBrief: Camurus Receives Approval In Canada For Oczyesa XR
Brief: Executive Sells About £279,000 Of Camurus Shares
Jefferies cuts Ipsen to 'underperform' on Somatuline competition risk
Brief: Camurus Says NDA Resubmission For CAM2029 In Acromegaly Accepted For Review By FDA
Camurus shares rise after Q2 revenue, operating profit beat